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Abstract The thrombin generation potential is an
in vitro measure for the capacity of an individual to
generate thrombin and recognized as a reflection of a
hypo- or hypercoagulable status. Measurement of the
in vivo thrombin activity, however, may be of clinical
significance. We evaluated a new assay for in vivo
thrombin activity and compared it to the in vitro
thrombin generation potential in patients with hemophi-
lia A (N = 15), oral anticoagulation for atrial fibrillation
(AF) (N = 20), subjects with active cancer (N = 21),
and healthy volunteers (N = 10). Thrombin activity was
measured with a commercially available oligonucleotide
enzyme capture assay in argatroban-stabilized plasma
samples. Thrombin generation potential was determined
with a commercially available assay in citrated plasma.
Thrombin activity was detected in 17 (30.4 %) patients
(mean 0.30 mU/ml [SD 0.80]), and in 39 patients
(69.6 %) no thrombin activity was present. In cancer
patients, thrombin activity was detected in 11 patients
(52 %) (range 0.14–5.00 mU/ml) and was particularly
increased in 3 patients with vessel-invasive tumors (1.2,
1.5, and 5.0 mU/ml). In AF patients, thrombin activity
was only measureable in two patients (10 %) (recent
hematoma [0.4 mU/ml] and recent ischemic stroke
[1.5 mU/ml]). Thrombin activity was detected in four
patients (27 %) with hemophilia (range 0.29–1.75 mU/
ml), all of whom had received a factor VIII infusion on
the same day. Thrombin activity did not correlate with
any of the parameters of the thrombin generation
potential. Only patients in acute procoagulatory states or
after clotting factor replacement had elevated in vivo
thrombin activity, which was, however, unrelated to the
in vitro thrombin generation potential.
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Introduction
Thrombin is a pivotal component of the coagulation cas-
cade, integrally connected in pathways that lead to blood
clotting as well as to endogenous anticoagulation and fib-
rinolysis [1, 2]. The capacity to generate thrombin from
circulating prothrombin is considered to reflect an indi-
vidual’s ability to react to vascular damage and to stop
bleeding [3], but low amounts of thrombin are also relevant
in preventing thrombosis via the protein C pathway [4].
Thrombin has a short half-life and naturally occurring
inhibitors, such as antithrombin, rapidly bind thrombin,
which makes the direct measurements of in vivo thrombin
difficult [5]. Assays that quantify the thrombin generation
potential are in vitro methods that utilize an added coag-
ulation trigger for initiating the formation of thrombin [6].
Elevated and reduced thrombin generation potentials in
patients are associated with hyper- and hypocoagulable
states, respectively, as well as with thromboembolic out-
comes [7–9].
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A novel assay for measuring thrombin activity has
recently been introduced by Mu¨ller et al. [10]. The method
is based on an oligonucleotide enzyme capture method that
enables the measurement of free thrombin in stabilized
plasma samples and is thus independent of an in vitro
coagulation trigger. Thus far, measurements of thrombin
activity have not been linked to clinical correlates, but very
low levels of thrombin activity were measured in plasma
from healthy donors compared to subjects with diagnosed
thrombophilia [11].
In our current method comparison, we investigated with
an exploratory approach how much free circulating
thrombin could be measured with the oligonucleotide
enzyme capture assay in a selection of clinical cases with
hypo- and hypercoagulable states and whether there is a
relationship between in vivo thrombin activity and in vitro
thrombin generation potential.
Patients and methods
Patient samples
Venous blood samples were obtained from patients with
confirmed severe hemophilia A, atrial fibrillation (AF), and
active cancer in routine care, who supplied written
informed consent for clinical surplus samples in accor-
dance with the vote of the local ethics committee. Control
samples were obtained from 10 healthy volunteers. Blood
was sampled from cubital venipuncture using a 21-gauge
needle, after discarding the first 8 ml of blood, and col-
lected without stasis into a citrate plasma vial (Vacuette,
Greiner-Bio One, Kremsmu¨nster, Austria; containing 1/10
volume sodium citrate at 0.129 mmol/l) and into an arga-
troban-containing vial (Thrombin blood collection tubes,
Sekisui Diagnostic, Pfungstadt, Germany). The reversible
formation of argatroban–thrombin complexes inhibits the
degradation of free thrombin in plasma. Vials were cen-
trifuged at 2500 g for 15 min at room temperature, divided
into aliquots, and stored at -80 C within 1 h of blood
draw. Prothrombin time (PT, Thromborel S, Siemens
Healthcare Diagnostics Products GmbH, Marburg, Ger-
many), activated partial thromboplastin time (aPTT,
Pathromtin SL, Siemens), diluted thrombin time (dTT,
Hemoclot, Hyphen Biomed, Neuville–sur–Oise, France),
and international normalized ratio (INR) were measured
with commercially available kits on an accredited process
with fresh blood samples.
Thrombin activity assay
Sample aliquots were thawed in a water bath for 15 min at
37 C. Thrombin activity was measured using a
commercially available fluorogenic assay (OLIGOBIND
Thrombin activity, Sekisui Diagnostic, Pfungstadt, Ger-
many) according to manufacturer instructions. Standards
and patient samples were pipetted in duplicate into separate
wells of the aptamer-coated microtiter plate and incubated
at room temperature for 1 h in the dark, before washing
four times with wash buffer. Addition of a thrombin sub-
strate and a fluorogenic substrate to the aptamer-bound
thrombin started the cleavage of the fluorogenic substrate.
We measured the increase in fluorescence at room tem-
perature with extinction at 360 nm and emission at 460 nm
over 30 min at 5-min intervals inside a fully automated,
computer-controlled microplate reader (BioTek,
FLX800). The rate of change in fluorescence is calculated
to thrombin activity (mU/ml) using a 6-point standard
curve. Manufacturer-specified limit of detection is
0.10 mU/ml thrombin, and the lower limit of quantification
is 0.35 mU/ml thrombin. We found a residual standard
error of 11.6 % for the third calibration point at 0.8 mU/ml
after 8 repeated measurements of the calibrators.
Thrombin generation assay
Thrombin generation was measured using a commercially
available fluorogenic assay (Technothrombin TGA, Tech-
noclone, Vienna, Austria) according to manufacturer
instructions and as described previously [12]. Coagulation
of the thawed platelet-poor plasma samples was initiated
with addition of the TGA RC low reagent, containing a
final concentration of 5 pM recombinant human tissue
factor lipidated in 3.2 lmol/l phospholipid micelles
(phosphatidylcholine [2.56 lmol/l] and phosphatidylserine
[0.64 lmol/l]). The generated thrombin cleaves the fluo-
rogenic substrate Z-Gly-Gly-Arg-AMC (1 mM, ? 15 mM
CaCl2) (Technoclone), while fluorescence was measured at
360 nm extinction and 460 nm emission on the same
microplate reader over a period of 120 min in 1-min
intervals. The parameters lag time, peak thrombin, time to
peak thrombin, velocity index [VI], and area under the
curve were used in the analysis. Prothrombin fragment
1 ? 2 [F1 ? 2] levels were measured as an indirect mea-
sure of thrombin with an enzyme-linked immunoassay
(Enzygnost F1 ? 2; Dade-Behring, Marburg, Germany)
according to manufacturer instructions.
Statistical methods
For the description of the study cohorts, we give continu-
ous variables of patient characteristics by mean and stan-
dard deviation (SD) and dichotomous variables by absolute
and relative frequency. We compared the parameters of
thrombin generation potential (peak thrombin, lag time,
time to peak, area under the curve as an expression of the
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endogenous thrombin potential [ETP] and velocity index
[VI]) and F1 ? 2 levels with the thrombin activity using
the Pearson correlation coefficient, as well as visually using
a scatter plot of thrombin activity versus peak thrombin
generation potential. Mean comparisons between the sub-
groups of patients and the healthy controls were calculated
with the Student’s t test, and a p value smaller than 0.05
was considered statistically significant. All calculations
were performed with SPSS (version 23, IBM, USA).
Results and Discussion
Clinical surplus samples were collected from 56 patients, 19
women and 37 men (21 cancer, 20 AF, and 15 severe
hemophiliaApatients) with amean age of 54.9 years (cancer
patients 59.6, AF patients 69.0 years, and hemophilia
patients 29.5 years). Entities of cancer were six lung, five
pancreas, three breast, two stomach, and five other cancers.
Hemophilia A patients had a mean baseline factor VIII
activity of 0.87 % (SD 1.4), and at blood sampling, a mean
FVIII activity of 8.4 % (SD 11.2). At the time of blood
collection, four patients with severe hemophilia (defined as
\1 % baseline factor VIII activity) had had prophylactic
FVIII replacement before blood collection and their mean
FVIII activity was significantly higher than the mean FVIII
activity of patients in their washout phase since the last
factor replacement (21.0 vs. 1.9 %, p = 0.002). AF
patients had a mean CHA2DS2-Vasc score of 4.1 (SD 1.4).
All AF patients were on continuous anticoagulation treat-
ment at the time of sampling and within the on-treatment
range, 4 on dabigatran (mean aPTT 56.6 s, STD 24.12;
mean dabigatran concentration [by dTT] = 127.5 ng/ml,
STD 195.0), 2 on apixaban (mean PT = 79.0 %, STD
4.24), 9 on rivaroxaban (mean PT = 67.6 %, STD 23.5),
and 5 on the vitamin K antagonist phenprocoumon (mean
INR = 1.88, STD 0.39).
The oligonucleotide enzyme capture assay detected
levels of thrombin activity in 17 patients (30.4 %) with a
mean of 0.30 mU/ml (SD 0.80), while no thrombin activity
at all was detected in 32 patients (69.6 %) and in all of the
healthy controls. In a previous investigation, with plasma
from healthy donors, the thrombin activity had been below
the assay’s lower limit of quantification and even limit of
detection [10]. Therefore, we were able to confirm with our
findings that in patients without ongoing coagulation there
is little to no free thrombin circulating. In part, this is due
to the very short half-life of thrombin, which is degraded
quickly in plasma [11]. Nonzero thrombin activity was
evenly distributed among men and women (31.8 and
31.6 %, without hemophilia patients), and mean age was
not significantly lower (56.5 years [SD 18.5] vs. 51.1 years
[SD 18.0], t test p = 0.32).
Overall patients and healthy volunteers, the mean peak
thrombin generation potential was 144.1 nM thrombin (SD
133.6 nM), with a mean lag time of 24.6 min (13.7 min), a
mean peak time of 33.6 min (20.4 min), a mean VI of
24.6 nM/min (33.4 nM/min), and mean ETP of 2208.1 nM
thrombin (1249.0 nM). The thrombin generation potential
parameters are shown separately for patient subgroups in
Table 1. Corresponding to previous findings, the parame-
ters of thrombin generation expressed a procoagulatory
state in cancer patients (Table 1), which has been associ-
ated with an elevated risk for occurrence of venous
thromboembolic events [13]. The mean F1 ? 2 level was
165.0 pmol/l (SD 110.3) and F1 ? 2 levels correlated with
all parameters of the thrombin generation over the entire
cohort (data not shown). Hemophilia A patients had
decreased parameters of thrombin generation potential
compared to healthy volunteers and the other patient
groups, indicating a reduced capacity for generating
thrombin in the event of bleeding, which has also been
associated with the severity of hemophilia as well as the
severity of the bleeding phenotype in hemophilia patients
[14, 15]. The means of the thrombin generation parameters
and F1 ? 2 levels in patients with AF were statistically
close to those of healthy volunteers, except for a signifi-
cantly longer lag phase and peak time (Table 1). These
findings indicate that within our selection of patients the
thrombin generation potential and the F1 ? 2 levels con-
sistently show a trend from a hypocoagulable state in
severe hemophilia A patients to a state of hypercoagula-
bility in cancer patients (Fig. 1).
However, we saw no correlation between all nonzero
thrombin activity measurements with the parameters of the
thrombin generation or the F1 ? 2 levels (Table 1; Fig. 2).
In the diverse selection of patients in this investigation, a
linear relationship between thrombin activity and thrombin
generation potential is not possible, because of the integral
connection of thrombin in pathways for clotting, endoge-
nous anticoagulation, and fibrinolysis. The thrombin
activity, which is below the limit of detection of the assay,
may have substantial effects on preventing wrongful
coagulation [4]. Also, an inverse relationship between
thrombin activity and thrombin generation could have been
possible. We could explain it with a coagulation process
that consumes the thrombin generation potential, indicated
by a high thrombin activity. A separate analysis within the
patient subgroups was not possible due to the small number
of patient samples with nonzero thrombin activity. In
cancer patients, thrombin activity was detected in 11
(52 %) patients (range 0.14–5.00 mU/ml) and was partic-
ularly increased in 3 patients with vessel-invasive tumors
(1.2, 1.5 and 5.0 mU/ml). In AF patients, thrombin activity
was only measureable in two patients (10 %): One patient
had peroneal palsy due to an acute hematoma (0.4 mU/ml),
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and the other patient had a recent history of ischemic stroke
(1.5 mU/ml). Whether the thrombin activity also correlates
with the expected increase in thrombin generation potential
in patients with acute ischemic stroke [16] is uncertain
without further data from samples from a larger cohort with
acute thromboembolic events. While differences in
thrombin generation potential on treatment with different
anticoagulants and at different concentrations were
described in previous studies [17–19], there is no evidence
for any effect of anticoagulant use or drug plasma levels on
thrombin activity levels from our data. The hemophilia
patients who had not received a factor VIII replacement
preceding the blood sampling had thrombin activity levels
beneath the level of detection and significant lower FVIII
levels (mean 1.9 (SD 2.3) vs. 21.0 (SD 11.3), t test
p = 0.002). Interestingly, thrombin activity was detected
in four patients (27 %) with hemophilia A (range
0.29–1.75 mU/ml), all of whom had received a prophy-
lactic factor VIII infusion on the same day and had higher
median FVIII activity. This is a novel finding describing a
response in thrombin activity from hemophilia patient
plasma after factor VIII replacement. The clinical appli-
cation of a thrombin activity assay may generate a novel
quality to measuring the activity of coagulation factor
replacement therapy in hemophilia patients or an alterna-
tive for the monitoring of bypassing agent therapy in
hemophilia patients with inhibitors [20], if the findings can
be reproduced in a larger cohort. Although unlikely, we can
presently not exclude that the factor concentrates contained
small amounts of thrombin.
The current study is a pilot study to investigate the
potential implications of the thrombin activity assay for
clinical practice in different cohorts of patients. To our
knowledge, there are currently no published studies
Table 1 Thrombin generation and thrombin activity measurements in separate subgroups of patients
Healthy
volunteers
(N = 10)
Cancer patients
(N = 21)
AF patients
(N = 20)
Hemophilia
patients A
(N = 15)
Cancer
patients
versus
healthy
volunteers
t test
p value
AF
patients
versus
healthy
volunteers
t test
p value
Hemophilia
A patients
versus
healthy
volunteers
t test p value
Pearson r with
thrombin
activity
(p value)
(N = 17)a
TG lag time
(min),
mean (SD)
20.2 (3.9) 13.27 (4.94) 28.2 (9.5) 38.57 (16.49) \0.001 0.003 0.001 -0.292 (0.255)
TG peak
thrombin
(nM),
mean (SD)
112.0 (58.7) 272.79 (124.61) 112.4 (107.1) 27.65 (37.21) \0.001 0.987 0.001 0.361 (0.155)
TG peak
time (min),
mean (SD)
33.1 (6.1) 19.05 (6.95) 43.5 (17.7) 41.43 (29.84) \0.001 0.025 0.307 -0.263 (0.309)
TG VI (nM/
min), mean
(SD)
9.8 (6.7) 58.13 (39.47) 13.8 (16.1) 1.76 (2.73) \0.001 0.340 0.004 0.304 (0.235)
TG ETP
(nM),
mean (SD)
2720.4 (924.2) 2808.28 (660.31) 2277.0 (1284.6) 934.25 (1165.15) 0.791 0.290 \0.001 0.323 (0.206)
Prothrombin
fragment
1 ? 2
(pmol/l),
mean (SD)
110.4 (50.5) 282.1 (103.9) 123 (76.9) 93.5 (25.9) \0.001 0.645 0.280 -0.051 (0.847)
Thrombin
activity
(mU/ml),
mean (SD)
0.00 0.47 (1.11) 0.10 (0.34) 0.20 (0.46) 0.065 0.230 0.115 1
The correlation between parameters of the thrombin generation and thrombin activity is shown by the Pearson correlation coefficient, and means
of the measurements are tested for equality by t test
AF atrial fibrillation, TG thrombin generation, VI velocity index, ETP endogenous thrombin potential
a Only patients with nonzero thrombin activity
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investigating this new enzyme capture assay for thrombin
activity in any clinical setting. We therefore chose a
heterogeneous group of patients in order to get an
impression of the potential clinical and scientific implica-
tions of the assay’s results. The small number of patients in
this investigation is a limitation, because only 30 % of
patients had thrombin activity levels above the limit of
detection and we were unable to perform more analyses
within the groups of patients. However, we showed that in
most patients with a hyper- or hypocoagulable status no
free thrombin is detectable with this assay. Unlike the
thrombin generation potential, thrombin activity therefore
does not stand for the presence of a state of coagulability
but for a depiction of an instantaneous level of thrombin in
plasma. This is indication for the occurrence of subclinical
coagulation, the complete clinical or experimental impli-
cations of which are yet to be elucidated. We saw, how-
ever, elevated levels of thrombin in patients with an acute
procoagulatory stimulus, which describes a new quality for
thrombin measurements. Whether the elevated levels of
in vivo thrombin activity may be reproducible for all
patients with acute procoagulatory states needs to be con-
firmed in larger cohorts of specifically selected patients.
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